文献速递烧伤创面修复

菠萝蛋白酶基酶性清创(Nexobrid®)在深二度及全层烧伤中的应用概览:证据评价

An Overview of the Use of Bromelain-Based Enzymatic Debridement (Nexobrid®) in Deep Partial and Full Thickness Burns: Appraising the Evidence.
PubMed 文献 · J Burn Care Res · 2018-01-01

该研究检索1986至2017年Pubmed、Embase和Web of Science数据库,纳入7项前瞻性研究(含4项随机对照试验),评价Nexobrid®相比传统手术标准清创的获益证据。多数获益有较强支持证据,但改善瘢痕质量和缩短创面愈合时间分别有至少3项反驳证据和1项轶事证据,疼痛发生率主要为轶事证据。

要点

  • Nexobrid®在缩短清创时间、减少手术需求、减少切除面积、减少自体移植需求方面有较强支持证据。
  • 改善瘢痕质量和缩短创面愈合时间分别有至少3项反驳证据和1项轶事证据。
  • 疼痛发生率主要为轶事证据,缺乏正式客观评估或队列研究。

核心结论

  • 尽管文献有限,Nexobrid®的获益在已发表的随机和单臂研究中是明显的。
  • 需要大量研究以进一步评价Nexobrid®的拟议获益。

研究设计与样本

  • 研究为文献综述,检索Pubmed、Embase和Web of Science数据库中1986年至2017年发表的涉及Nexobrid®用于深二度及全层烧伤的研究。
  • 共纳入7项设计良好的前瞻性研究,其中4项为随机对照试验。
  • 将研究按支持证据、反驳证据和轶事意见分类评价其拟议获益。

主要发现

  • 提取出6项与Nexobrid®使用相关的拟议获益:缩短完成清创时间、减少手术需求、减少烧伤切除面积、减少自体移植需求、缩短创面闭合时间和改善瘢痕质量。
  • 大多数拟议获益有较强支持证据,来自对照试验的轶事意见极少,但改善瘢痕质量和缩短创面愈合时间分别有至少3项反驳证据和1项轶事证据。
  • 疼痛发生率也进行了评价,主要为轶事证据,缺乏正式客观评估或队列研究。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出文献缺乏(lack of literatures available)。
  • 原文指出需要大量研究以进一步评价Nexobrid®的拟议获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent introduction of rapid bromelain-based enzymatic debridement has been increasingly popular in its use in nonsurgical debridement in deep partial and full thickness burns. We designed this study to evaluate the evidence suggested by current studies on the perceived benefits of using Nexobrid® compared with traditional surgical standard of care in burns wound debridement. A comprehensive search on electronic databases Pubmed, Embase, and Web of Science was done to identify studies published between 1986 and 2017 involving the use of Nexobrid® in deep partial and full thickness burns. Studies were evaluated for proposed benefits and categorized under supporting evidence, contradicting evidence, and anecdotal opinions. Seven well-designed prospective studies met the inclusion comprising four randomized controlled trials. Six proposed benefits associated with the use of Nexobrid® were extracted including reduced time to complete debridement, need for surgery, area of burns excised, need for autograft, time to wound closure, and improved scar quality. Most proposed benefits have strong supporting evidences with minimal anecdotal opinions from controlled trials except the proposed improvement in scar quality and reduced time to wound healing that had at least three refuting evidence and one anecdotal evidence. Incidence of pain was also evaluated and was mainly anecdotal lacking formal objective assessment or cohort study. Despite the lack of literatures available, the benefits of Nexobrid® are evident in published randomized and single arm studies. Large number of studies is needed to aid further evaluating the proposed benefits of Nexobrid®.

来源:J Burn Care Res,查看原文。版权归原作者所有。

引用

  1. Loo YL, Goh BKL, Jeffery S, et al. An Overview of the Use of Bromelain-Based Enzymatic Debridement (Nexobrid®) in Deep Partial and Full Thickness Burns: Appraising the Evidence. J Burn Care Res. 2018. PMID: 29579268. doi:10.1093/jbcr/iry009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。